Merck posted $16.6 billion in Q2 2026 sales as LIPFENDRA won FDA approval and KEYTRUDA QLEX gained traction, even as a Terns acquisition charge drove a GAAP loss.
AbbVie’s Q2 2026 earnings show $16.99 billion in net revenues (+10.2%), record Skyrizi and Rinvoq growth, a $10.9 billion Apogee Therapeutics acquisition, and updated full-year adjusted EPS guidance.
Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent’s record €5.2 billion quarter and a 48.3% jump in pharma launches, prompting an upgraded full-year outlook.
IQVIA Q2 2026 results show revenue up 8.7% to $4.368 billion, Adjusted EPS of $3.15, and a raised full-year 2026 outlook, driven by record R&D Solutions bookings and accelerating Commercial Solutions growth.
GSK’s Q2 2026 results show core operating profit up 7% to £2.8 billion, driven by Specialty Medicines and Vaccines, alongside plans for 20+ Phase III trial starts and the $10.6bn Nuvalent acquisition.
AstraZeneca’s H1 2026 results show Total Revenue climbing 9% to $30,672 million and Core EPS up 12% to $5.21, powered by Oncology and Rare Disease growth, 30 new regulatory approvals, and fresh licensing deals for Zegfrovy and TQC3721 — as the company reaffirms its $80 billion 2030 revenue ambition.
Danaher Corporation (NYSE: DHR) reported strong second-quarter 2026 financial results, generating revenue of $6.265 billion (+5.5% YoY) and non-GAAP adjusted diluted earnings per share (EPS) of $1.94 (+8.0% YoY), with both key metrics outperforming Wall Street consensus estimates. Non-GAAP core sales grew 3.0% overall and 4.5% when excluding post-pandemic respiratory testing normalizations, driven by a rebound across Life Sciences workflows and continued adoption of clinical diagnostics menus.
Novartis Q2 2026 results show a return to sales growth, with net sales up 3% to $14.4 billion on strong demand for Kisqali, Kesimpta, Scemblix, and Pluvicto, as the company reaffirmed its full-year 2026 guidance and advanced key pipeline programs including Fabhalta and Rhapsido.
This Johnson & Johnson Q2 2026 Analysis breaks down JNJ’s second-quarter results $25.3 billion in worldwide sales, raised full-year guidance, and standout performance from its oncology and immunology drug portfolio.
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
